B-lactoglobulin-Modified Mesoporous Silica Nanoparticles, A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells

Fenbendazole, which is an anthelmintic, was encapsulated into succinylated beta-lactoglobulin-modified, amine-functionalised mesoporous silica nanoparticles to protect the drug throughout gastrointestinal tract and improve its anticancer effects against prostate cancer.

The data resulting from this study include the Higuchi kinetic model of the drug release and the toxicity effects of the prepared formulations against HEK-293 cells.

本数据集收录了将抗蠕虫药苯并咪唑封装于琥珀酰化β-乳球蛋白修饰的、胺基功能化的介孔二氧化硅纳米粒子中，以保护药物在胃肠道全程释放并增强其对前列腺癌的抗癌效果的研究成果。研究数据包括药物释放的Higuchi动力学模型以及所制备制剂对HEK-293细胞的毒性效应。